AGEN · Agenus Inc
$7.49
-0.77 (-9.32%)
At close · Aug 20
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the timing and completion of these transactions are not entirely within our control, in accordance with applicable accounting standards, substantial doubt exists about our ability to continue as a going concern for at least one year after the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 7, 2026
Market Cap
$337.20M
Shares
45.02M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.49
Open$8.22
Day$7.31–8.25
52W close$2.77–8.30
Avg vol 30d7.9M
Short int6.2M · 13.8% float · 3.1d
Short vol54%
Last earningsAug 6, 2026
DataApr 2024–Aug 2026
Filing10-Q · Aug 7
Raw chart and full-history price indicators begin at the captured split on Apr 12, 2024; bars on opposite sides are not compared.
Up next
Next earnings call
Nov 7, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+87%
above
Price vs 50-day avg
+44%
above
RSI (14)
59
neutral
MACD trend
Negative
52-week position
85%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+21%
trailing
6-month return
+125%
trailing
YTD return
+139%
this year
Relative strength
+114%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+19% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.84% of float · ▼ -11.7% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
105 holders — mid 3-yr range
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+90%
Y/Y
EPS growth
+100%
Y/Y
Free cash flow
$-77.2M
Balance sheet
$41.7M
net debt
Quant / Vol
risk profile
Volatility
118%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
9.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Dec 31, 2024
Annualized burn rate
· by the middle of this year
$50M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+87%
Bullish
Price vs 50-day avg
+44%
Bullish
RSI (14)
59
Neutral
MACD trend
Negative
Bearish
52-week position
85%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+19% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.84% of float · ▼ -11.7% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
105 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $7 · 85%
Range high $8
vs 200-day avg +87%
vs 50-day avg +44%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| net revenue from the AAC and paid NPP programs | $6.37M | FY2026 Q2 | — |
|
|
|||
| patients treated with botensilimab and/or balstilimab | 1,300 | Phase 1 and Phase 2 clinical trials (cumulative) | — |
| countries with physician inquiries | 30 | year ended December 31, 2025 | — |
| median overall survival in heavily pretreated MSS mCRC without active liver metastases | 21 | 2H 2025 (ESMO-GI 2025) | — |
| patients in BOT+BAL clinical dataset | 1,200 | year ended December 31, 2025 | — |
| patients in pan-tumor analysis | 400 | 2H 2025 (ESMO 2025) | — |
| physician inquiries from early access programs | 200 | year ended December 31, 2025 | — |
| two-year overall survival in heavily pretreated MSS mCRC without active liver metastases | 42% | 2H 2025 (ESMO-GI 2025) | — |
| two-year overall survival pan-tumor activity | 39% | 2H 2025 (ESMO 2025) | — |
| Zydus contingent payment triggered | $20M | March 2026 | — |
| Zydus escrow amount | $7.5M | January 2026 | — |
| Zydus transaction expenses | $5.8M | January 2026 | — |
| Zydus upfront capital | $91M | January 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AGEN
this stock
Agenus Inc
|
$337.20M | +138.5% | +89.9% | — | 13.8% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Apr 12, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AGEN | +7.0% | +21.0% | +124.9% | -0.1% | +138.5% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +9.0% | +17.7% | +113.8% | -2.2% | +126.7% |
Key facts
CIK
1098972
CUSIP
00847G804
13F (30d)
100 filings
99 filers
Visit website
Investor relations